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Abstract The thymus is a central lymphoid organ with
crucial role in generating T cells and maintaining homeo-
stasis of the immune system. More than 30 peptides, ini-
tially referred to as “thymic hormones,” are produced by
this gland. Although the majority of them have not been
proven to be thymus-speciWc, thymic peptides comprise an
eVective group of regulators, mediating important immune
functions. Thymosin fraction Wve (TFV) was the Wrst thy-
mic extract shown to stimulate lymphocyte proliferation
and diVerentiation. Subsequent fractionation of TFV led to
the isolation and characterization of a series of immunoac-
tive peptides/polypeptides, members of the thymosin fam-
ily. Extensive research on prothymosin  (proT) and
thymosin 1 (T1) showed that they are of clinical signiW-
cance and potential medical use. They may serve as molec-
ular markers for cancer prognosis and/or as therapeutic
agents for treating immunodeWciencies, autoimmune dis-
eases and malignancies. Although the molecular mecha-
nisms underlying their eVect are yet not fully elucidated,
proT and T1 could be considered as candidates for can-
cer immunotherapy. In this review, we will focus in princi-
ple on the eventual clinical utility of proT, both as a tumor
biomarker and in triggering anticancer immune responses.
Considering the experience acquired via the use of T1
to treat cancer patients, we will also discuss potential
approaches for the future introduction of proT into the
clinical setting.
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AAK cells Anti-CD3-activated killer cells
BRM Biologic response modiWer
CDDP Cisplatin
CML Cell-mediated lympholysis
CTL Cytotoxic T lymphocyte(s)
CY Cyclophosphamide
DC Dendritic cell(s)
DL Dalton’s lymphoma
DTIC Dacarbazine
5-FU 5-Fluorouracil
HMGB1 High mobility group box 1
HSP Heat sock protein
IFN Interferon
IL Interleukin
LAK cells Lymphokine-activated killer cells
3LL carcinoma Lewis lung carcinoma
MHC Major histocompatibility complex
NK cells Natural killer cells
NSCL cancer Non-small cell lung cancer
pI Isoelectric point
PBL Peripheral blood lymphocyte(s)
PBMC Peripheral blood mononuclear cell(s)
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PMN Polymorphonuclear(s)
ProT Prothymosin alpha
s.c. Subcutaneous
TACE Transarterial chemoembolization
TAM Tumor-associated macrophages
T1 Thymosin alpha 1
T4 Thymosin beta 4
TFV Thymosin fraction V
TLR Toll-like receptor(s)
TNF Tumor necrosis factor
VP-16 Etoposide
Introduction
The thymus gland as a central lymphoid organ plays a cru-
cial role in developing, maturing and diVerentiating many
of the cellular components of the immune system and is
considered essential for normal immune function. Until the
early 60s, the gland was thought to be vestigial. At this
time, its importance was documented by reports showing
that the immune system of neonatally thymectomized
rodents was generally crippled and an incapability to resist
infections and histoincompatible transplants was noted
[1–3]. The gland’s involution with age results in a decrease
of the levels of thymus-derived hormones [4] and a deW-
ciency in immune reactivity, accompanied by an increase in
cancer incidence and age-related diseases [5]. Thus, research
eVorts focused on the detection and identiWcation of thymic
humoral messages, namely complex thymic fractions and a
series of structurally deWned peptides [5].
Goldstein and colleagues were the Wrst to report the puri-
Wcation of a thymic extract that stimulated lymphocytopoi-
esis and enhanced in vivo immune cell proliferation in
mouse lymph nodes [6]. A year later, this lymphocytopoi-
etic factor was puriWed, chemically characterized and given
the name “thymosin” [7]. Subsequently, Goldstein’s
research team succeeded in further purifying a highly active
preparation from bovine thymus, termed thymosin fraction
V (TFV). In order to produce suYcient quantities of this
fraction and thus explore TFV’s properties, a new method,
including 5 sequential steps of heat treatment, acetone and
ammonium sulfate precipitation, ultraWltration and gel
Wltration, was developed [8].
When tested in vivo, TFV and its component parts were
able to enhance immune functions in newborn mice and to
augment the survival of mice that had undergone thymec-
tomy [9]. A similar activity was demonstrated in vitro in
lymphocytes of immune-suppressed humans, where TFV
restored, to almost normal levels, their deWcient immune
responses [10]. In addition, Dauphinee and colleagues
reported that TFV administration in animals with autoim-
mune diseases resembling human lupus erythematosus led
to the retreat of some of the symptoms [11]. Finally, TFV
was shown to exert in vitro antiproliferative eVects in sev-
eral neoplastic cell lines, including murine neuroendocrine
pituitary adenoma and glioma [12], human acute T lympho-
blastic [13] and promyelocytic leukemias [14]. In animals,
treatment with TFV conferred resistance to Dunning [15]
and murine lymphoblastic leukemias [16].
All these in vivo and in vitro immunomodulatory proper-
ties of TFV became the pretext for further investigating and
analyzing its components. EVorts toward this direction
showed that TFV consisted of 10–15 basic components and
20 or more secondary ones, with molecular weights varying
between 1,000 and 15,000 Da. A system of nomenclature
was developed to distinguish and characterize the individ-
ual peptides in TFV. These were consequently divided into
three groups (identiWed by the Greek letters alpha [], beta
[] and gamma []), according to their isoelectric point (pI).
Group  comprised peptides with pI < 5, group  those with
pI between 5 and 7 and group  peptides with pI > 7. Pep-
tides from each group were, and still are, indicated with a
subscript, 1, 2, 3, etc., that denotes the order of their isola-
tion and identiWcation from TFV. Depending on whether
they are biologically active or not, they are further charac-
terized as thymosins or simple peptides/polypeptides,
respectively [17].
The majority of the polypeptides, isolated so far from
TFV, belong to - and -thymosins, whereas none of them
belong to -thymosins. The family of -thymosins is mainly
represented by thymosin 1 (1), a 28-amino acid peptide
that was the Wrst member of this family isolated from TFV
and prothymosin  (proT), a 109–112 amino acid long
polypeptide (depending on the mammalian species), proven
to be 1’s precursor molecule, and the natural polypeptide
present within the cells [18]. hymosin 4 (4) is the
major representative of the -thymosin family [19]. T4
along with proT retains the major activity of TFV and this
is the main reason why, more than 25 years after their isola-
tion, they are still in the scientiWc spotlight (Table 1).
The dual—intracellular and extracellular—role of proT
Although initially referred to as a “thymic hormone,” proT
demonstrates some unique properties: it is not thymus-spe-
ciWc, as it is encountered in many lymphoid, but also non-
lymphoid organs [20]; it is highly conserved during evolu-
tion, as it presents extended homology in its primary struc-
ture among mammalian species [19]; and it is a universal
polypeptide surmounting approximately 10,000 copies per
cell [21]. The ubiquitous and wide distribution of proT in
tissues and cells implied its participation in important
cellular molecular circuits. Accumulating evidence avail-
able to date suggests a dual role for the polypeptide: in the123
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the polypeptide exerts an immunomodulatory eVect.
We now know that proT is crucial for the survival and
proliferation of normal cells [21]. Several reports have
demonstrated that proT mRNA increases in lymphocytes
[21, 22] and in NIH3T3 cells stimulated to divide [23], and
proT antisense oligomers inhibit myeloma cell-division
[24]. ProT prevents apoptosis through inhibiting apopto-
some formation [25], regulates DNA remodeling during
proliferation, controls gene expression by directly binding
to free-core histone H1 [26] and increases the accessibility
of micrococcal nuclease to chromatin [27]. An association
between the oncogene c-myc and proT has also been
reported; Eilers and coworkers showed that activation of
c-myc in quiescent rat and mouse Wbroblasts led to rapid
increase in transcription of proT and elicited reentry into
and progression through the cell cycle [28]. Most recently,
proT-mediated nuclear import of Keap1, an inhibitor of
the stress-sensor Nrf2, was proposed as a novel mechanism
promoting cell survival [29].
Extracellularly, it has been suggested that proT acts as
a biologic response modiWer (BRM) stimulating immune
responses. The initial observations came from in vivo stud-
ies in animals, where proT was able to protect immuno-
suppressed mice against infections caused by Candida
albicans and other opportunistic infections [30]. When
added in lymphocyte cultures, proT enhanced antigen or
mitogen-induced T cell proliferation, increased the produc-
tion of interleukin (IL)-2 and the expression (both in num-
ber and in density) of its receptor on T cells [31, 32] and
upregulated major histocompatibility complex (MHC) class
II antigen expression on human monocytes [33]. ProT was
also shown to stimulate the cytotoxicity of natural killer
(NK) cells [34] and the induction of lymphokine-activated
killer (LAK) cells activity [35]. To clarify the molecular
mechanisms underlying these immunomodulatory func-
tions, Cordero and colleagues used radioiodinated, biologi-
cally active proT to study the binding sites of the molecule
on human lymphoblasts [36]. Two binding sites, of low and
high aYnity, were identiWed, both of which were speciWc
for proT, but not T1. In a subsequent study, Piñeiro and
colleagues revealed three binding “partners” for proT in
the membrane of lymphoblasts, which formed a cap-like
structure on one of the cell’s poles and associated with lipid
rafts [37, 38]. Most recently, proT was suggested to ligate
toll-like receptor (TLR)-4, signal through the TRIF-depen-
dent pathway and induce interferon (IFN)- production
[39]. The concept currently under investigation is that
proT functions as an alarmin, which when experimentally
proven would explain the proT-induced activation of
innate and adaptive immunity [40] and provide a link
between the two discrete functions of the molecule.
Nevertheless, in view of the two aforementioned activi-
ties of proT, over the years, several research groups have
explored the possibility that the polypeptide may serve as a
molecular marker for cancer prognosis and/or as a thera-
peutic agent for treating immunodeWciencies, autoimmune
diseases and malignancies [41]. Herein, we will review data
acquired with respect to proT’s (in comparison with T1)
potential use as a cancer biomarker and as an option in the
treatment of cancer.
ProT as a cancer (bio)marker. Use in cancer diagnosis/
prognosis
ProT is probably the most well-studied thymosin with
respect to its relevance to malignant cell transformation,
and several studies have been carried out to investigate the
levels of proT in a variety of cancer cells.
In view that cancer cells are highly proliferative, it was not
surprising to detect high proT content, both at mRNA and
protein level, in malignant tissues. With respect to the
former, in rats, high proT mRNA expression was detected
in mitogen-stimulated thymocytes and splenic T cells [42], in
proliferating pituitary tumors [43] and during the initial stage
(Wrst 6 weeks) of hepatic carcinogenesis, where proT
mRNA remained almost tenfold higher as the neoplasm pro-
gressed. In situ hybridization revealed that overexpressed
proT mRNA was restricted to neoplastic nodules in the
hepatic tissue and to tumor cells invading blood vessels [44].
Table 1 Major representatives 
of structurally characterized 
- and -thymosins
Thymosin Year of isolation/
identiWcation
Number of 
amino acids
Localization Ref.
-Thymosins
Thymosin 1 1966 28 Ubiquitous, cytoplasm, serum, urine [7]
Prothymosin  1984 109–112 Ubiquitous, nucleus, cytoplasm, serum, urine [18]
Parathymosin  1985 101 Ubiquitous, nucleus, cytoplasm, serum [19]
-Thymosins
Thymosin 4 1979 44 Ubiquitous, nucleus(?), cytoplasm, serum [19]
Thymosin 9 1982 42 Ubiquitous in calf, cytoplasm [19]
Thymosin 10 1983 42–44 Ubiquitous in man, mouse and rat, cytoplasm [19]123
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with those of c-myc in colon [45] and liver cancer [46] and
N-myc in neuroblastoma [47] (Table 2). However, although
lung cancer tissues showed similarly elevated proT
mRNA expression, this was not paralleled by c-myc
mRNA increase [48], indicating that simultaneous tran-
scription of the two genes does not occur in all cancer
types. In the last report, the possibility of using proT lev-
els as a biomarker was proposed, as high proT mRNA was
associated with poorer prognosis of lung cancer patients.
ProT mRNA was also found signiWcantly elevated in
rhabdomyosarcoma [49] and in well-diVerentiated thyroid
carcinomas compared to thyroid adenomas and goiters [50].
By developing a highly sensitive real-time polymerase-
chain reaction assay able to determine proT levels in very
small samples, such as those acquired through Wne-needle
aspiration, the authors suggested the potential usage of
proT as a novel proliferation marker for cancer develop-
ment. From another aspect, of particular interest is the
study of Ojima and coworkers [51], which opens new pros-
pects for the use of the polypeptide in the clinic: upregula-
tion of proT mRNA in rectal cancer, predicts resistance to
and eVectiveness of radiotherapy.
At the protein level, results from cancer tissues veriWed
the fact that aggressive tumors contain more proT. We
showed that proT levels, as quantiWed by highly sensitive
and speciWc radioimmunoassays for the amino- and the car-
boxy-termini of the polypeptide, were highly elevated in
breast and colon cancers compared to the nearby healthy
tissues [52]. At the same time, Dominguez and coworkers
conWrmed our observation, reporting high proT content in
primary ductal carcinomas of the breast [53], and went fur-
ther correlating tumor proT levels with disease outcome.
SpeciWcally, they estimated that patients with cancer tissue
proT content over 124 ng/mg had a higher probability of
developing distant metastases.
The clinical signiWcance of these Wndings was next
investigated. The aforementioned research teams showed
that expression of proT in human breast cancer
(a) depends on the proliferation status of the tumor [54],
(b) is associated with already established prognostic factors
describing the metastatic potential of the tumor [54],
(c) predicts the rate of tumor recurrence [55] and (d) relates
to the overall survival of the patient [54, 55]. Therefore,
both studies, although performed independently, came to
the same conclusion that high proT levels in primary
breast tumors can be considered as an early “sign” corre-
lated with a worse outcome of the disease.
Later on, Suzuki and colleagues studied proT expres-
sion with respect to the diVerentiation and progression of
human prostate cancers. By immunohistochemistry and
immunoblotting, they showed that proT levels consecu-
tively increased as prostate tissue progressed from normal
epithelium, through prostatic intraepithelial neoplasia to
carcinoma [56]. Particularly, in prostate cancer lesions,
intense nuclear staining for proT was also reported [57].
Subsequent complementary research investigated proT
expression in human bladder cancer using tissue micro-
arrays [58]. A statistically signiWcant enhancement of
proT expression, also from the clinical aspect, was
Table 2 Prothymosin  as a biomarker for cancer prognosis in humans
Type of cancer Material detected Correlation with Ref.
Bladder Protein in tissue and urine Cancer detection; cancer grade; follow-up [58, 67]
Breast Protein in tissue and serum Cancer grade; tumor recurrence; 
lymph node metastasis; distant metastases; 
risk of death; overall survival
[52–55, 65]
Colon mRNA in tissue c-myc expression [45, 52]
Gastric Protein in tissue – [63]
Head and neck Protein in tissue Tumor recurrence [62]
Liver mRNA in tissue; protein in tissue c-myc expression; poor prognosis [46, 60]
Lung mRNA in tissue Poor prognosis [48]
Neuroblastoma mRNA in tissue N-myc expression [47]
Pituitary Protein in tissue Tumor recurrence [61]
Prostate Protein in tissue Cancer cell diVerentiation; tumor progression [56, 57]
Rectal mRNA in tissue EVectiveness of radiotherapy [51]
Rhabdomyosarcoma mRNA in tissue – [49]
Thyroid mRNA in tissue; 
protein in tissue and serum
Cancer cell diVerentiation [50, 66]
Upper urinary tract Protein in tissue Tumor recurrence [59]123
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adjacent tissues, which was most prominent in tumors of a
higher grade. In upper urinary tract cancer, tumor recur-
rence was associated with proT overexpression, but only
when the polypeptide was localized in the tumor-cell cyto-
plasm [59]. These Wndings support the potential usage of
proT as a diagnostic tool, maybe also as a therapeutic tar-
get, for cancers of the urinary tract. Finally, immunostain-
ing of hepatocellular carcinomas [60], pituitary tumors [61]
and head and neck carcinomas [62], but not of gastric can-
cers [63], associated high proT content with aggressive
tumors and poor prognosis.
As proT is an intracellular protein, studies to reveal its
relevance to cancer were performed until recently in
malignant tissues and their extracts. Such analysis of
proT content has the advantage of directly “viewing” the
mRNA or protein content of the tumor itself, but also has
the main disadvantage that suYcient amounts of tissue are
not always available. In principle, cancer biomarkers are
determined in biologic Xuids, usually blood plasma/serum
or urine. Indeed, soon after its identiWcation, proT was
detected in human blood [64], its presence attributed
either to leakage from damaged leukocytes or “secretion”
from proT-rich cells via an as yet unknown mechanism.
Nevertheless, to date, proT detection in cancer patients’
sera is reported in only two studies (a) in breast cancer
patients [65] and (b) in a secretome analysis of thyroid
carcinomas [66]. Unfortunately, no correlation of blood
proT levels with cancer development and/or prognosis
was found.
However, an interesting report revealed that urine proT
has the potential of being a useful tumor marker for the
detection and follow-up of bladder cancer [67]. Urine sam-
ples, obtained from healthy volunteers, patients with uri-
nary infection or bladder transitional and non-transitional
cell carcinomas, were assayed for their proT levels by a
speciWc enzyme-linked immunosorbent assay. Subsequent
comparison of the results showed that (a) urine proT was
higher in newly diagnosed bladder cancer patients,
(b) patients with non-transitional cell carcinoma tumors had
lower proT in their urine compared to patients with blad-
der tumors, and (c) during a 3-month follow-up, urine
proT content increased when residual or a recurrent tumor
was present after treatment. Although the cross-reactive
material present in urine was not identiWed as intact proT,
this study opens new perspectives for the introduction of
proT as a novel cancer marker in the clinic, particularly
for urinary tract carcinomas (Table 2).
The use of T1 as a cancer biomarker
As already mentioned, T1 was the Wrst -thymosin iso-
lated, and therefore, its relevance to human disease, includ-
ing cancer, was investigated early on. In contrast to the
study of proT expression mainly in cancer tissues, T1
content was investigated, almost exclusively, in plasma of
patients with cancer. In the initial report by Hersh and col-
leagues [68], plasma T1 levels were higher in patients
with various solid tumors, hematologic malignancies and
immunodeWciencies. In lung cancer patients, mean T1
plasma levels, as determined by a sensitive radioimmunoas-
say speciWc for T1, were elevated compared to normal
individuals, suggesting that plasma T1 could be used as a
biomarker for lung cancer prognosis [69]. Further investi-
gations aimed at determining the role of T1 in lung cancer
revealed that its levels correlated neither with the stage nor
the pathological subtype of the cancer. Similarly, patients
with gastric cancer had elevated plasma T1, which did not
correlate with the clinical stage of the disease [70]. Never-
theless, plasma T1 was higher in patients with lymph node
metastases that stained positive for T1. The latter Wnding
led the authors to conclude that higher T1 expression may
be related to the more aggressive nature of the tumor.
It is of interest to note that the relevance of 1 levels
with cancer development and/or prognosis is not as estab-
lished as that of proT. In our opinion, this observation is
reasonable and results from the fact that the natural poly-
peptide, present intracellularly and participating in cell pro-
liferative events, either normal or abnormal, is proT [52].
Consequently, the presence of T1 in malignant tissues or
in cancer patients’ plasma could be either the result of
extensive proT cleavage and release, possibly associated
with uncontrolled cancer cell growth, or the outcome of a
randomly produced by-product of abnormal processes often
seen in malignant lesions.
A-thymosins in cancer therapy
During the last decade, scientiWc interest has turned toward
therapies that may restore immunity under conditions of
immune-suppression associated with cancer, based on the
assumption that a strong immune response will result in
successful tumor growth inhibition. Among other thymic
peptides tested alone or in combination with other BRMs
such as cytokines, proT and T1 have been suggested as
candidate molecules for cancer immunotherapy. Actually,
synthetic 1 formulated for subcutaneous (s.c.) injection
(thymalfasin), under the trade name Zadaxin (SciClone
Pharmaceuticals) [71], is the only -thymosin widely tested
in the clinical setting in humans for over 25 years, for the
treatment of a variety of diseases, from cancer to viral
infections and AIDS. Because of its excellent safety record,
Zadaxin is currently approved in over 30 countries world-
wide, as an immunostimulant. The drug is proposed to act
by increasing the expression of MHC class I molecules,
the numbers of CD4+, CD8+ T and NK cells and the123
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tosis and decreasing IL-4 and IL-10 production.
ProT as an immunotherapeutic tool
As already stated, proT exhibits some intriguing extracel-
lular properties and is now classiWed in the family of
BRMs. In the early 90s, evidence with respect to the anti-
cancer potential of proT came to light, although the mode
of action of the polypeptide still remained obscure
(Table 3). ProT’s eYcacy was studied in three successive
reports in an aggressive in vivo animal tumor model. Spe-
ciWcally, therapeutic administration of proT (ca. 3 g/
mouse over 3 weeks) in DBA/2 mice inoculated with syn-
geneic leukemic L1210 cells inhibited the development of
ascites in 20% of the animals and prolonged the survival of
40–60% of them by several weeks compared to controls (10
vs 2 weeks, respectively) [72]. A potential mechanism of
action of the polypeptide was linked to the activation of
peritoneal exudate cells in proT-treated mice, since they
were shown to produce six to eight times higher levels of
tumor necrosis factor (TNF)- and thus exhibit cytotoxicity
against various cell lines, both TNF--sensitive and TNF--
resistant. A detailed analysis of the immunological altera-
tions induced upon proT treatment was subsequently
performed in the same animal model [73]. As expected,
splenocytes from proT-treated mice exhibited signiW-
cantly higher ex vivo cytotoxic activity against NK-sensi-
tive and NK-resistant targets and most importantly against
the syngeneic tumor cells. Indeed, proT was shown to
increase both the number and the activation level of NK
and CD3+ T cells, as well as of the CD8+ T cell population.
In vitro, proT-induced stimulation of splenocytes addi-
tionally revealed that lymphocyte proliferation and cytotox-
icity were sustained by the high concentrations not only of
TNF- but also of IL-2 produced in response to pro, and
this most likely also occurs in vivo [74]. Of utmost impor-
tance was the observation that when proT was adminis-
tered in vivo simultaneously with the L1210 tumor cells,
the polypeptide provoked the generation of tumor-speciWc
CD8+ cytotoxic T lymphocytes (CTL), which, subse-
quently, lysed the syngeneic targets in a MHC-restricted
fashion [74]. This enhanced CTL activity was supported by
concomitantly induced L1210-speciWc CD4+ T cells and by
the production of IL-2 and TNF- in the spleen, peritoneal
cavity and probably other lymphoid organs. This last report
clariWed an important issue regarding the activity of proT;
mice receiving only proT in principle developed non-
MHC-restricted cytotoxic activity (mediated by NK and
LAK cells), whereas mice concomitantly receiving proT
and L1210 tumor cells developed both MHC-restricted
(CTL) and non-MHC-restricted cytotoxic activities and
survived longer. The overall results suggest that in vivo,
proT acts upstream lymphocyte activation and its mode of
action is IL-2-dependant. Moreover, depending on the pres-
ence of tumor-speciWc antigenic peptides or not, proT can
“manoeuver” anticancer immune responses shifting them
toward the appropriate, most eVective route of stimulation.
Following the studies in mice, the eVect of proT was
next tested in humans (Table 3). Since cancer patients are
generally characterized by decreased cytotoxic activity and
dysfunction in lymphokine production, proT’s ability to
restore these deWciencies was investigated in vitro, using
immune-impaired peripheral blood lymphocytes (PBL)
from cancer-bearing individuals [75]. ProT normalized, to
a great extent, the signiWcantly reduced cell-mediated
lympholysis (CML) and NK cell activity, which were by
deWnition much lower in patients with advanced malignan-
cies of various types compared to normal individuals. This
restoration of immune responses was attributed to the
appropriate modiWcation of the levels of prostaglandin E2
(PGE2) and IL-2, cytokines that were down- and up-regu-
lated by proT, respectively. Accordingly, both CML and
NK cell activity improved almost to normal, indicating that,
in vitro, the polypeptide is capable of partially or even fully
restoring cancer-induced immune deWciencies [75].
With respect to a speciWc type of cancer, results from a
study in cells from melanoma patients showed that mono-
cyte disorders could be partially normalized by proT [76].
In fact, both normal donor- and melanoma patient-derived
monocytes preincubated with proT alone or in the pres-
ence of IFN- to enhance antigen presentation inhibited
SK-MEL-28 melanoma cell growth in vitro. Moreover,
monocytes from patients at earlier stages (I/II) of the dis-
ease showed higher tumoristatic activity than those at stage
III and tended to respond better to preincubation with
proT followed by IFN- activation. The restorative eVect
of proT on the impaired activity of LAK cells derived
from melanoma patients was additionally shown [77].
However, lymphocytes from individual patients demon-
strated a broad range of LAK cell responsiveness to proT,
which was dependant, among other factors, on the stage of
the disease; cells from patients with early stage I/II melano-
mas were those that responded better to proT treatment in
vitro.
The eVect of proT was also studied on PBL and mono-
cytes derived from colorectal tumor patients [78–80]. Once
more, proT in synergy with IL-2 could eYciently stimu-
late patients’ LAK cell activity only at early stages (Dukes
A/B) of the disease [78, 80]. ProT acted via increasing the
adhesion of lymphocytes to tumor targets (namely of
SW620 colon carcinoma), and this eVect was mediated by
increased secretion of the deWcient IL-2-induced IFN-.
Phenotypic analysis of the proT (in synergy with IL-2)-
activated lymphocytes revealed that the polypeptide
enhanced the expression of CD56, CD16/56 on NK cells, of123
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CD11a on lymphocytes. Colon cancer patient-derived
monocytes in vitro stimulated with proT and/or IFN-
exhibited elevated average antitumor activity against
SW620 colon carcinoma cells, paralleled by production and
secretion of reduced concentrations of transforming growth
factor- and PGE2 and increased levels of the proinXam-
matory cytokines IL-1 and TNF-, as determined in the
culture supernatants [79, 80]. The aforementioned results
suggested that in vitro proT can partially, however signiW-
cantly, restore lymphocyte deWciencies present in cancer
patients, by selectively regulating some functions of mono-
cytes. The latter, in response to pro, secrete cytokines
and create a suitable cytokine milieu facilitating lympho-
cyte activation. It should be noted that proT’s activity
highly depends on the stage of the disease, at least in mela-
noma and colon cancer patients, suggesting that the poly-
peptide can reverse mild but not severe tumor-induced
immune-suppression.
A combination of two or more immunomodulatory mol-
ecules acting synergistically has often been shown to
induce improved anticancer eVects. Anti-CD3 monoclonal
antibody has been reported to augment the cytotoxic func-
tions of lymphocytes and has been successfully used for the
large-scale expansion of non-MHC-restricted cytotoxic
subsets for adoptive cellular immunotherapy, referred to as
anti-CD3-activated killer (AAK) cells. Baxevanis and
coworkers combined anti-CD3 with proT and demon-
strated that anti-CD3 plus proT can improve AAK cyto-
toxicity of peripheral blood mononuclear cells (PBMC)
derived from cancer patients with various malignancies,
such as breast, ovarian and lung [81]. ProT increased
PBMC MHC- and non-MHC-restricted killing of tumor tar-
gets, but most importantly of autologous tumor cells by
anti-CD3-activated CD8+ and CD56+ lymphocytes, imply-
ing that this thymic polypeptide might be active in vivo
also.
Along the same line, combining proT with low-dose
IL-2 enhanced the induction of LAK cell activity [82],
potentiating in particular the cytotoxicity of the CD16+
CD2- subset [83], whereas synergy between IL-2 and
proT increased the generation of tumor-speciWc cytotoxic
T lymphocytes against autologous human carcinomas [84].
In the study of Voutsas and colleagues [84], PBMC
obtained from cancer patients were cocultured in vitro with
autologous tumor cells in mixed lymphocyte-tumor cul-
tures in the presence of proT and/or IL-2. The combina-
tion proT/IL-2 increased the proliferation of CD4+ T cells
and the generation of MHC class I-restricted autologous
tumor-speciWc CTL. An important issue clariWed by this
study was that in order for proT to exert its beneWcial
eVect on CTL, the concomitant presence of autologous
Table 3 Prothymosin  as a therapeutic agent for cancer treatment
Cancer/species Synergy with EVect Ref.
In vitro
Breast/human Anti-CD3 Improvement of MHC- or non-MHC-restricted cytotoxicity [81, 86]
§fMLP Increase of chemotaxis, oxidative responses and cytotoxicity of PMN
Colorectal/human IL-2 Enhancement of LAK activity; increased expression of cytotoxic 
surface molecules on NK, NKT-like cells and lymphocytes
[78–80, 86]
§IFN- Decrease of monocyte-derived TGF- and PGE2 production; increase 
of monocyte-derived IL-1 and TNF- production; monocyte-induced 
colon cancer cell cytotoxicity
§fMLP Increase of chemotaxis, oxidative responses and cytotoxicity of PMN
Lung/human Anti-CD3 Improvement of MHC- or non-MHC-restricted cytotoxicity [81]
Melanoma/human §IFN- Enhancement of PBMC-induced melanoma cell cytotoxicity [76, 77, 86]
IL-2 Restoration of LAK cell activity
§fMLP Increase of chemotaxis, oxidative responses and cytotoxicity of PMN
Ovarian/human Anti-CD3 Improvement of MHC- or non-MHC-restricted cytotoxicity [81]
Various tumors/human – Restoration of CML and NK cell activity; increase of PBMC-derived 
IL-2 production; decrease of PBMC-derived PGE2
[75, 84]
IL-2 Increase of CD4+ T cell proliferation; generation of tumor-speciWc CTL
In vivo
Leukemia/mouse – Prolongation of survival [72, 74]
Enhancement of NK cell- and induction of LAK cell- activity 
in splenic lymphocytes
[73]
Increase of TNF- production; induction of tumoricidal activity 
by peritoneal exudate cells; selective expansion of leukemia-speciWc T cells
[74]123
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Indeed, the absence of either subpopulation resulted in
strong impairment of both proliferative and cytotoxic
responses, which could not be reversed even if proT was
added later on, suggesting that proT-stimulated responses
demand initial collaborative interactions between CD4+,
CD8+ T cells and antigen-presenting cells.
Our research team assembled this accrued data on the
mode of action of proT in a cellular model. We used pro-
teomics to detect intracellular protein changes induced in
mononuclear cells, derived either from normal donors or
cancer patients, over the course of a 3-day stimulation with
proT [85]. Based on the identiWcation of immunologically
signiWcant molecules overexpressed downstream proT
activation, we proposed that initially, proT triggers mono-
cyte stimulation via TLR-ligation and signaling and
enhances antigen presentation through MHC class II mole-
cule upregulation. This event consequently promotes
monocyte-T cell immune synapse. Subsequently, activated
monocytes produce proinXammatory cytokines (IL-1), and
highly activated, via T cell receptor triggering, T cells pro-
duce IL-2 and proliferate. Finally, proT-stimulated PBMC
express high levels of surface integrins (CD2) and of intra-
cellular cytotoxic molecules (perforin), both of which con-
tribute to the enhancement of their cytotoxic activity. Our
results are in agreement with most recent data, suggesting
that proTa is an endogenous TLR-4 ligand, which can
induce the production of type I IFNs from macrophages
[39].
ProT exerts multiple immunological activities in vitro,
and with this in mind, proT’s ability to enhance polymor-
phonuclear leukocyte (PMN) properties was also investi-
gated [86]. ProT-stimulated PMN isolated from patients
with colorectal, breast and melanoma tumors showed
increased chemotaxis and enhanced oxidative responses.
ProT-stimulated PMN became also more cytotoxic versus
HCT-116 colon tumor target cells. The outcome of the lat-
ter study, in conjunction with the already analyzed eVects
of proT, implies that the polypeptide acts pleiotropically
and is able to improve distinct functions of immune cells
under particular conditions of immunosuppression.
Although extensive research on the mechanisms of
action underlying proT’s anti-tumor immunological
eVect has been performed [36], the polypeptide has not
yet been introduced in immunotherapeutic protocols for
treating cancer patients. There are several reasons for this
ambiguity, one of the main being the unclear extracellular
molecular mechanism of action of proT. Another is
proT’s length and acidic nature, as it cannot be easily
synthesized and/or puriWed [87]. Most recent reports dem-
onstrate that various areas of the molecule possess diverse
activities, for example, amino acids 50–89 of proT
inhibit HIV-1 activity [39], proT1–29 and proT102–
112 exert anti-necrosis eVect [88] (Table 4). We recently
reported that the decapeptide spanning residues 100–109
of proT’s carboxy-terminus (proT(100–109); TKKQK
TDEDD) is the actual immunoactive area of the polypep-
tide and a most potent lymphocyte stimulator [89].
ProT(100–109) induces PBMC proliferation and cyto-
toxicity, promotes the maturation of dendritic cells (DC),
adopts a -sheet conformation, and its eVects are
sequence-speciWc and comparable to that of intact proT.
In an earlier study, we had shown that a slightly smaller
segment (103–109) was also eVective in restoring the
immune function of PBMC obtained from cancer patients
in vitro [90]. As for today, the peptide TKKQKTDEDD is
known to be generated in vivo upon caspase-cleavage of
proT during apoptosis [91, 92], and additional mecha-
nisms of its generation and immunoreactivity are cur-
rently being investigated in our laboratory. Therefore,
besides the scientiWc interest in elucidating the immuno-
logical role of proT and revealing a link between its two
distinct functions, intracellular/proliferative and extracel-
lular/immunomodulatory (Fig. 1), the identiWcation of a
smaller proT-related peptide with immunomodulatory,
possibly also with anticancer activity, may provide a
novel compound that could help improve immune deW-
ciencies associated with cancer.
Table 4 Prothymosin  
peptides with recorded activity Fragment (amino 
acid residues)
Nomenclature Activity Ref.
ProT(1–28) 1 Immunomodulatory; DC activation; anticancer; 
antiviral; antifungal; vaccine enhancement
[17]
ProT(1–24) Des (25–28) T1 n.t. [19]
ProT(1–35) T11 Antifungal [19]
ProT(50–89) Anti-HIV-1 [39]
ProT(100–109) Immunomodulatory; DC maturation; anticancer [89]
ProT(30–109) ProT1–29 Anti-necrotic [88]
ProT(1–101) ProT102–112 Anti-necrotic [88]
n.t. not tested123
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trials
An early sign that T1 might be active against tumors and
of clinical value was Wrst suggested about 25 years ago,
when Favalli and coworkers revealed that T1-treatment
for 4 days, followed by a single injection of IFN-/,
restored lymphocyte activity in cyclophosphamide (CY)-
suppressed tumor-bearing mice [93]. T1 stimulated the
tumor-speciWc T and NK cell-mediated cytotoxic activity
of lymphocytes, whereas mice bearing Lewis lung (3LL)
carcinoma administered CY and subsequently treated with
T1+ IFN-/ [94] or IL-2 [95], showed an increase of
tumor-inWltrating lymphoid cells and consequently a dra-
matic and rapid tumor regression. In the same mouse
model, T1 was shown to synergize with the cytokine
cocktail IRX-2 (pooled supernatant of phytohemagglutinin-
stimulated normal donors’ PBL), leading to signiWcant
improvement in the survival of the animals [96].
T1 was further shown to be beneWcial in rodents inocu-
lated with other types of tumors (Table 5). When accompa-
nied by low-dose IL-2 or IFN-/, CY-treated mice
challenged with Friend’s leukemia cells experienced com-
plete tumor regression and a signiWcant percentage of them
Fig. 1 A proposed scenario explaining how proT exerts its dual (in-
tra- and extracellular) biologic eVect. In a normal cell, proT is mainly
localized in the cell nucleus, where it regulates gene expression and cell
proliferation. Under abnormal conditions, cells responding to danger
signals die via necrosis or apoptosis. During necrosis, cell components,
such as intact proT, are released extracellularly, due to cell membrane
disruption. During apoptosis, proT is relocalized in the cytoplasm,
where its carboxy-terminus is cleaved by caspases. ProT’s truncation
generates the immunoactive peptide, proT(100–109), which polymer-
izes into -sheet structures and is excreted from the cell. Extracellularly,
both proT and proT(100–109) activate innate-immunity cells, for
example, macrophages, monocytes, DC and neutrophils via TLR-liga-
tion and signaling. Stimulation of monocytes and DC enhances antigen
presentation and strengthens their synapsis with T cells. DC stimulate T
cell proliferation and cytokine production, thus providing a favorable
environment for enhancing speciWc and non-speciWc cytotoxicity. Con-
sequently, eVector cells produce lytic molecules (e.g., perforin) and
upregulate adhesion-molecule expression (e.g., CD2). In the presence
of speciWc antigens, CD8+ T cell cytotoxicity is enhanced. 
secretion of cytokine;  stimulation of proliferation123
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model in rats, administration of 5-Xuorouracil (5-FU) fol-
lowed by T1 and low-dose IL-2 increased peripheral
blood NK cell activity, leading to considerable reduction in
liver metastases and prevention of extra-hepatic tumor
spreading [98]. When the same research team optimized the
aforementioned triple chemo-immunotherapeutic combina-
tion, an increase in the number of CD4+ and CD8+ T cells
in the periphery was observed, which prevented extra-
hepatic metastases, and thus considerably increased the
average survival time of the animals [99].
To elucidate the mode of action of T1, Shrivastava and
colleagues extensively studied murine macrophages selec-
tively activated by the peptide [100]. When mice bearing
spontaneous T cell lymphoma (Dalton’s lymphoma (DL))
were treated with T1, their tumor-associated macrophages
(TAM) were directly responsive to the peptide, were highly
activated, produced high levels of IL-1, TNF-, reactive
oxygen intermediates, nitric oxide and exhibited increased
pinocytosis, phagocytosis, antigen presentation and tumor
cytotoxicity. When tested ex vivo, these TAM eYciently
diVerentiated to DC with enhanced antitumor activity. Most
importantly, adoptive transfer of T1-treated peritoneal
macrophages in DL-bearing mice delayed tumor growth
and prolonged their survival [100]. The outcome of this
study demonstrated for the Wrst time that, similarly to
proT, T1 acts upstream lymphocyte activation, by stimu-
lating macrophages, rendering them capable of directly
destroying cancer cells, and by indirectly activating other
immune cells via cytokine secretion.
Clinical studies with T1
These animal studies indicated that T1 could be eVective
in humans, in principle for immune restoration following
chemotherapy, and several trials to evaluate its eYcacy
Table 5 Thymosin 1 as a therapeutic agent for in vivo cancer treatment
Cancer/Species Treatment EVect Ref.
Preclinical/animal studies
Colorectal/mouse T1 + IL-2 + 5-FU Increase of NK cell activity; increase of CD4+ and CD8+ cells 
in the periphery; prevention of extra-hepatic tumor spread; 
reduction in liver metastases; increase of survival
[98, 99]
Leukemia/mouse T1 + (IL-2 or IFN-/) + CY Complete tumor regression; cure [97]
Lung/mouse T1 + IFN-/ Increase of tumor-inWltrating lymphoid cells [94–96]
T1 + IL-2 Rapid tumor regression
T1 + IRX-2 Increase of survival
Lymphoma/mouse T1 TAM activation; increase of TAM-derived IL-1, TNF-, nitric oxide, 
reactive oxygen intermediates; increase of pino/phagocytosis, 
antigen presentation and cytotoxicity of PMN
[100]
Melanoma/mouse 1 + IFN-/ +CY Restoration of lymphocytic activity; stimulation of tumor-speciWc 
and NK cell cytotoxicity
[93]
Clinical studies
NSCL/human T1 Maintenance of normal CD4+ T cell counts; increase of 
relapse-free and overall survival
[101]
T1 + IFN--2 + CDDP + V16 Complete/partial response in some patients; increase 
of median survival
[103]
T1 + IFN- + ifosfamide Maintenance of normal CD4+, CD8+ T cell and NK cell counts; 
decrease of hematologic toxicity; increase of average response; 
increase of time-to-progression
[104]
T1 + IFN- + DTIC Increase of NK cell cytotoxicity; increase of CD4+ T cell counts [105]
Melanoma/human T1 + IL-2 + DTIC Complete response/stable disease in some patients; 
increase of median survival
[102]
T1 + IFN- + DTIC Complete/partial response in some patients;
increase of median survival; 
increase of median time-to-progression
[105]
T1 + DTIC Increase of patients experiencing tumor response; 
increase of duration of response; increase of median survival; 
increase of progression-free survival
[106]
Liver/human T1 + TACE Increase of CD3+, CD8+, CD16/56+ cell counts; increase of time 
to recurrence; increase of median and overall survival; 
full protection from bacterial infections
[107–109]123
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group of Alan Goldstein [101], where in post-irradiated
non-small cell lung (NSCL) cancer patients (42 individu-
als), administration of T1 (900 g/m2/day) for 14 days
showed normalization or maintenance of normal CD4+ T
cell percentages and improvement of relapse-free and over-
all survival. Several years later in 1994 [102], patients with
metastatic melanoma (46 in total) were treated with dacar-
bazine (DTIC), followed by 2 s.c. doses of T1 (2 mg/dose)
and IL-2. Complete response was recorded in 2 patients and
stable disease in 5, median survival was 11 months, and the
toxicity of the regimen was acceptable. Further, a phase II
study was conducted in 1995 to evaluate the eYcacy of cis-
platin (CDDP) and etoposide (VP-16) combined with T1
(1 mg/day; 11 doses s.c.) and low-dose IFN--2 for the
treatment of 56 patients with advanced NSCL cancer [103].
Two patients experienced complete and 22 a partial
response to treatment, which, as a whole, was well toler-
ated; median survival was 12.6 months. Although the che-
motherapeutic drugs depressed NK cell activity and
lymphocyte number, their adverse eVects were less promi-
nent in patients also receiving T1 + IFN--2. A subse-
quent phase II randomized trial was conducted by Salvati
and colleagues [104]. Twenty-two patients with advanced
NSCL cancer were randomized to receive only ifosfamide
(chemotherapy) or ifosfamide followed by T1 (same dose
as in [103]) + low-dose IFN- (chemo-immunotherapy).
The latter enhanced the average response rate to 33%
compared to 10% of chemotherapy alone. Although these
percentages were not signiWcant, the diVerence in time-
to-progression was statistically signiWcant, and patients
receiving chemo-immunotherapy showed reduced hemato-
logic toxicity and no decrease in CD4+, CD8+ T and NK
cell counts [104]. Following the initial study of Lopez and
colleagues [102], the evaluation of the eVect of T1 was
extended in a phase II open trial for advanced metastatic
melanoma [105]. Out of 20 stage III/IV patients treated
with DTIC + T1 (1 mg/day; s.c.; 8 doses at chemotherapy
intervals for 3–9 cycles) + low-dose IFN-, 5 patients expe-
rienced complete and 5 more a partial response. Median
survival and median time-to-progression were 11.5 and
5.5 months, respectively, and no toxicity was recorded. As
in NSCL cancer, patients treated with the triple combina-
tion showed improved NK cell activity and higher CD4+ T
cell counts compared to those receiving only DTIC. Taken
altogether, melanoma and NSCL cancer patients who were
administered T1 did not beneWt dramatically in terms of
complete response or survival time, but incorporation of the
peptide to standard chemotherapy regimes improved the
functionality and counts of some lymphocyte subsets (NK
cell cytotoxicity; CD4+/CD8+ T cell ratio).
Most recently, the largest, thus far, multicenter open ran-
domized trial in metastatic melanoma patients evaluating
T1 administration was completed. Maio and coworkers
[106] recruited 488 stage IV patients from 64 centers and
treated them with DTIC + IFN-, DTIC + T1 or
DTIC + IFN- + T1 (1.6–6.4 mg; s.c.; 8 doses at chemo-
therapy intervals for 6 cycles). After a 24-month follow-up,
the Wndings of this study were that adding T1 to chemo-
therapy (a) increased the number of patients experiencing
tumor response (11.2 vs 4.1%); (b) increased their median
overall survival by 2.8 months (9.4 vs 6.6); (c) improved
the duration of response from 1.9 to 23.2 months;
(d) increased 6-month progression-free survival by 12%
(21.1 vs 9.1%); and (e) was safe and non-toxic. In agree-
ment with the initial study of Schulof et al. [101], T1
could potentiate the eYcacy of DTIC with or without the
concomitant addition of IFN-.
Three more trials, set on a diVerent basis, evaluated the
therapeutic potential of T1 in patients post-hepatectomy or
with unresectable hepatocellular carcinoma treated with
transarterial chemoembolization (TACE). In the Wrst [107],
T1 (900 g/m2; s.c.; twice weekly for 6 months) pro-
longed patients’ survival and increased signiWcantly the
percentages of CD3+, CD8+, CD16/56+ cells after 1 month
of treatment. In the second [108], T1 increased patients’
time to tumor recurrence by 3 months and median survival
by 2 months. Finally, in the most recent phase II random-
ized trial of Gish and colleagues [109], the same dose of
peptide, but administered to the patients almost daily
(1.6 mg; s.c.; 5-times weekly for 6 months), conferred full
protection from bacterial infections and increased overall
survival for over 13 months compared to T1-untreated
patients.
As with any novel agent introduced in the clinic, an
important issue that should be discussed at this point with
respect to the use of T1 in humans is toxicity and safety.
In the most recent methodical review of Wolf and col-
leagues [110], these parameters were extensively analyzed
among other thymic peptides also for T1. According to the
aforementioned clinical studies, T1 doses up to 6.4 mg
were safe, did not induce toxicity and lacked severe side
eVects. When given in combination with chemotherapy, no
adjunctive toxicity or interference between chemo- and
immunotherapy was recorded; on the contrary in many
cases, T1 allowed a general reduction in intrinsic toxicity
of chemotherapeutic drugs. Immunological monitoring of
some of the recruited patients showed a cyclic variation in
immune responses, with a dramatic decline after chemo-
therapy and a boosting after T1 treatment, which occurred
repeatedly during each cycle of therapy. Unfortunately, as
this, unique for the moment, overall evaluation concludes,
only weak evidence supports the clinical eVectiveness of
1 on the management of cancer, although some patients
undergoing chemotherapy might beneWt via T1-induced
reduction in the risk of infectious complications.123
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clinical implications
All the aforementioned in vitro and in vivo studies with
proT, as well as the experience gained from the clinical
trials conducted for T1, have brought to light some inter-
esting observations. Firstly, the levels of proT in cancer
tissues, maybe also in biologic Xuids such as urine, should
be appropriately validated in order for the polypeptide to be
used as a potential biomarker for cancer prognosis and pro-
gression. In the case of a heterogeneous disease like cancer,
such a study will require samples from a cohort of many
cancer patients, classiWed on the basis of their tumors’ his-
tological characteristics, stage of the disease, treatment
approach and long-term follow-up, in conjunction with
clinical responses and the values of already established bio-
markers. Secondly, due to its elevated expression in cancer
cells, targeting intracellular proT, consequently inhibiting
its activity, is predicted to cause the inability of cancer cells
to proliferate and the induction of cancer cell apoptosis.
The eventual development and in vivo testing of proT-
speciWc inhibitors could provide a future option for antican-
cer treatment. Thirdly, administration of proT can provide,
via a variety of mechanisms, some as yet unknown, the
appropriate environment (i.e., a stimulating cytokine
milieu) that enhances the eYcacy of tumor-speciWc and
non-speciWc eVector cells, as already shown in vitro and in
animals in vivo. As current approaches for cancer patient
treatment and management encourage adjuvant therapy,
proT could be an excellent candidate that could act coop-
eratively with other cancer therapies, for example, chemo-
therapy and/or irradiation. Finally, from experience to date,
administration of relatively high concentrations of proT in
animals and of T1 in animals and humans lacks toxicity
and severe adverse eVects.
The apparent question that arises is how can the same
molecule, proT, adopt diVerent properties and carry out
discrete and diVerent functions depending on whether it is
localized inside or outside the cell. This paradox is not
unique to proT. It has already been described for a series
of proteins, prominent examples being heat-shock protein
(HSP) 90 and high mobility group protein B1 (HMGB1)
[111]. Both HSP90 and HMGB1 have well-characterized
intracellular functions (as a molecular chaperone and a reg-
ulator of transcription, respectively), but when excreted, by
non-classical ER-Golgi-independent secretory pathways,
have documented extracellular roles, related to immuno-
modulation (as proinXammatory cytokine-like mediators)
[112, 113]. HSP90 and HMGB1 interact with TLR, possi-
bly also with other pattern recognition receptors (PRR) and
sensitize innate immune cells (e.g., DC), thus promoting
adaptive immune responses. These endogenous molecules
are now classiWed in the diverse group of factors termed
“alarmins,” to which more molecules are constantly being
added. In fact, thymosins are now considered as putative
alarmins, as they share several common characteristics and
modes of action with HSP and HMGB [40]. In the case of
proT, these shared properties were further complemented
by the recent Wnding that in human macrophages, proT
signals via ligating TLR4, the most promiscuous of the
TLR, binding also HSP90 and HMBG1 [39]. This data con-
Wrmed our previous observation that proT-stimulated
human monocytes upregulated the expression of IRAK4
[85].
From a practical viewpoint and in relevance to antican-
cer treatment, HSP90 and HMGB1 have recently been pro-
posed as target molecules for developing novel anticancer
strategies, and clinical trials have already been scheduled
[114, 115]. Thus, our suggestion that proT per se can be
targeted to inhibit cancer cell development is not promiso-
rial and could provide a novel means of anticancer treat-
ment. Furthermore, taking as paradigms HSP90 and
HMGB1, proT could act as an adjuvant stimulating
immune responses to speciWc peptides or tumor antigens,
without causing severe adverse eVects. Unpublished data
from our laboratory show that in the presence of speciWc
HER-2/neu epitopes, DC matured with proT or its immu-
noactive decapeptide, proT (100–109) [89], not only
exhibit the appropriate phenotype, but are functionally
competent to induce HER-2/neu-speciWc CD4+ and CD8+
T cells responses in vitro (Ioannou et al. manuscript in
preparation). It is of interest to note that a smaller peptide
deriving from HMGB1 has been reported to possess similar
immune functionalities as the parental molecule [116].
The use of TLR ligands as adjuvants is a matter of
intense investigation, as they are critical compounds for the
success of antitumor vaccination. Notable examples are
CpG oligodeoxynucleotides signaling through TLR9, sin-
gle- or double (poly-I:C)-stranded RNA, ligating TLR7/8
and 3, imiquimod, a TLR7 agonist and monophosphoryl
lipid A (MPLA), a TLR4 agonist, the latter being the only
adjuvant approved for human use since alum [117]. The
recent phase I/II trial in prostate cancer patients vaccinated
with synthetic peptides combined with imiquimod proved
that TLR7 coactivation was beneWcial for the induction of
strong antitumor immunity and the generation of clinical
responses [118]. Therefore, at this stage, it would be quite
challenging to propose proT or its C-terminal fragment as
new adjuvant candidates to enhance the eYcacy of cancer
vaccines.
Conclusion
Considering the distinct properties of proT, the next
step should be research aimed primarily at independently123
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chemo-, radiotherapy and/or antitumor vaccination and
maybe, its potential use in predicting cancer outcome.
Using the appropriate control groups, randomized trials on
cancer patients may oVer the opportunity making advances
in cancer treatment in the near future.
Accrued data point to the design of clinical studies inte-
grating either the full length polypeptide or, preferably, its
immunoactive fragment(s) (Table 4), as adjuvants to cur-
rently applied vaccination regimes for treating cancer
patients. The lessons learned so far suggest that in order to
verify the immunostimulating eYcacy of proT, adminis-
tration of the polypeptide, or of its immunoactive frag-
ment(s), at chemotherapy intervals, for deWnitely more than
one chemotherapy cycle and possibly for a prolonged
period of treatment, could be a therapeutic choice.
At this point, and albeit intensive research followed by
published studies/trials on the ways of using this polypep-
tide in humans needs to be supplied, it is worth mentioning
that proT is available in the form of a “drug” [119], and
indications, dosage and administration instructions for its
use in patients are provided in the above mentioned web-
site.
After almost three decades of research, the initial notion
that the thymic peptide proT might be useful for treating
human diseases remains promising. In the case of cancer
where immune system integrity is of the utmost impor-
tance, the use of proT, most likely in combination with
other immune modulators, still appears to oVer potential.
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